About: Design of a Multi-epitope Vaccine against SARS-CoV-2 using Immunoinformatics approach

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Design of a Multi-epitope Vaccine against SARS-CoV-2 using Immunoinformatics approach Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Design of a Multi-epitope Vaccine against SARS-CoV-2 using Immunoinformatics approach
Creator	Abed, Atena Alizadeh, Morteza Arvejeh, Pooria Chermahini, Amini Mobini, Gholam-Reza Pourhossein, Behzad Safaei, Mohsen Sanami, Samira Zandi, Milad
Source	Elsevier; Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused COVID-19 disease in China. So far, no vaccine has licensed to protect against infection with COVID-19, therefore an effective COVID-19 vaccine needed. The aim of this study was to predict antigenic peptides of SARS-CoV-2 for designing the COVID-19 vaccine using immunoinformatic analysis. In this study, T and B-cell epitopes of S protein were predicted and screened based on the antigenicity, toxicity, allergenicity, and cross-reactivity with human proteomes. The epitopes were joined by the appropriate linker. LT-IIc as an adjuvant was attached to the end of the structure. The secondary and 3D structure of the vaccine was predicted. The refinement process was performed to improve the quality of the 3D model structure; the validation process is performed using the Ramachandran plot and ProSA z-score. The proposed vaccine's binding affinity to the HLA-A11: 01 and HLA-DRB1_01: 01 molecule was evaluated by molecular docking. Using molecular dynamics, the stability of vaccine-HLA complexes was also evaluated. Finally, in silico gene cloning was performed in the pET30a (+) vector. The findings suggest that the current vaccine may be a promising vaccine to prevent SARS-CoV-2 infection.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1016/j.ijbiomac.2020.07.117
bibo:pmid	32682041
has license	no-cc
sha1sum (hex)	add2d6d531398dd43adae803b328adb6beb306d9
schema:url	https://doi.org/10.1016/j.ijbiomac.2020.07.117
resource representing a document's title	Design of a Multi-epitope Vaccine against SARS-CoV-2 using Immunoinformatics approach
has PubMed Central identifier	PMC7362859
has PubMed identifier	32682041
schema:publication	Int J Biol Macromol
resource representing a document's body	covid:add2d6d531398dd43adae803b328adb6beb306d9#body_text
is schema:about of	named entity 'Immunoinformatics' named entity 'vaccine' named entity 'vaccine' named entity 'HLA-A' named entity 'allergenicity' named entity 'amino acid sequence' named entity 'public health' named entity 'Root Mean Square Fluctuation' named entity 'epitope' named entity 'epitope' named entity 'epitopes' named entity 'IFN-γ' named entity 'neutralizing antibodies' named entity 'alleles' named entity 'protein' named entity 'X-ray crystallography' named entity 'amino acids' named entity 'RMSF' named entity 'angstroms' named entity 'GC content' named entity 'reverse vaccinology' named entity 'amino acid residues' named entity 'protein structures' named entity 'aliphatic' named entity 'ligand' named entity 'BamHI' named entity 'HLA-A11' named entity 'virus' named entity 'immune responses' named entity 'probability' named entity 'molecular weight' named entity 'CTL' named entity 'coronavirus' named entity '3.5' named entity 'restriction enzymes' named entity 'vaccine' named entity 'proteome' named entity 'antigenicity' named entity '2.35' named entity 'vaccine' named entity 'molecule' named entity 'B-cell' named entity 'strong immune' named entity 'E. coli' named entity 'non-allergenic' named entity 'higher aliphatic' named entity 'epitope' named entity 'complex molecules' named entity '3.2%' named entity 'instability index' named entity 'E. coli' named entity 'HLA' named entity 'molecule' named entity 'secondary structure' named entity 'yeast' named entity 'molecule' named entity 'Recognition sites' named entity 'vaccine' named entity 'vaccine' named entity 'Reverse vaccinology' named entity 'TIP3P' named entity 'physicochemical' named entity 'molecule' named entity 'peptides' named entity 'multiepitope' named entity 'Coronavirus' named entity 'vaccine' named entity 'peptide' named entity 'chlorine' named entity 'instability index' named entity '2.0' named entity 'vaccine' named entity '1.08'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software